Introduction: In Prader-Willi syndrome (PWS), abnormal body composition with decreased lean body mass (LBM) and skeletal muscle (SM) volume have been related to an altered GH secretion. The scope of the study was to test the hypothesis that GH treatment have favourable effects on SM characteristics and motor performance in adults with PWS. Methods: Fifteen PWS adult obese subjects (nine males and six females, age 19-35 years, BMI 37.7-59.9 kg/m2) were investigated before and after 12 (GH12) and 24 (GH24) months of GH treatment. SM cross sectional area (CSASM) and attenuation (ATTSM) were determined with computed tomography at lumbar and mid-thigh level. Maximal handgrip isometric strength (SHG) and isokinetic knee extension peak torque (PTKE) were measured. Motor performance was evaluated with different indoor walking tests (WT), exercise endurance (TE) was assessed with a treadmill incremental test to exhaustion. Results: GH treatment significantly increased LBM (GH12: p<0.05; GH24: p<0.05), reduced percentage of body fat (GH12: p<0.05; GH24: p<0.05) and augmented CSASM and ATTSM of both lumbar (GH12: p<0.01; GH24: p<0.001) and thigh muscles (GH24: p<0.05). SHG increased by 7% at GH12 (p<0.05) and by 13% at GH24 (p<0.001). PTKE extrapolated at 0 angular velocity was significantly higher at GH24 (p<0.01) and TE rose by 13% (p<0.05) and 17% (p<0.05) before exhaustion at GH12 and GH24, while no change was detected with WT. Conclusions: Long term GH treatment in adult PWS patients improves body composition, muscle size and quality, and increases muscle strength and exercise tolerance.
Skeletal muscle characteristics and motor performance in response to growth hormone treatment in adults with Prader-Willi syndrome.
Giovanna Rizzo;
2013
Abstract
Introduction: In Prader-Willi syndrome (PWS), abnormal body composition with decreased lean body mass (LBM) and skeletal muscle (SM) volume have been related to an altered GH secretion. The scope of the study was to test the hypothesis that GH treatment have favourable effects on SM characteristics and motor performance in adults with PWS. Methods: Fifteen PWS adult obese subjects (nine males and six females, age 19-35 years, BMI 37.7-59.9 kg/m2) were investigated before and after 12 (GH12) and 24 (GH24) months of GH treatment. SM cross sectional area (CSASM) and attenuation (ATTSM) were determined with computed tomography at lumbar and mid-thigh level. Maximal handgrip isometric strength (SHG) and isokinetic knee extension peak torque (PTKE) were measured. Motor performance was evaluated with different indoor walking tests (WT), exercise endurance (TE) was assessed with a treadmill incremental test to exhaustion. Results: GH treatment significantly increased LBM (GH12: p<0.05; GH24: p<0.05), reduced percentage of body fat (GH12: p<0.05; GH24: p<0.05) and augmented CSASM and ATTSM of both lumbar (GH12: p<0.01; GH24: p<0.001) and thigh muscles (GH24: p<0.05). SHG increased by 7% at GH12 (p<0.05) and by 13% at GH24 (p<0.001). PTKE extrapolated at 0 angular velocity was significantly higher at GH24 (p<0.01) and TE rose by 13% (p<0.05) and 17% (p<0.05) before exhaustion at GH12 and GH24, while no change was detected with WT. Conclusions: Long term GH treatment in adult PWS patients improves body composition, muscle size and quality, and increases muscle strength and exercise tolerance.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.